Mickey isn’t the only mouse trying to wriggle out of the clutches of the masters of code.
- Animation World Network
Canada last week refused to grant a patent for a genetically modified mouse.
Unlike the US, EU and Japan, Canada denies that Harvard’s scientists invented anything when they manipulated mouse genes. Its Supreme Court says the university doesn’t deserve a patent - at least not until the politicians have had a chance to think the ethics of biotech over.
- National Post
As with Mickey, business concerns slam into public concerns here.
It doesn’t make much business sense for patented genes to be freely accessible. After all, you don’t want your rivals rummaging through your research work.
This isn’t just a standard big business line. As biotech develops, smaller firms, entrepreneurial boffins often, universities even, are entering the market as niche developers. Like artists, writers, coders and other intellectual property creators, they want to safeguard their work so they can be properly rewarded.
Fine, but when it comes to biotech, sole ownership of this kind of information isn’t in the public interest. Charging for access is likely to discourage research. Ideas develop most rapidly, most fruitfully through free exchanges of information. And it goes against common sense, moral sense, for private groups to have monopolies over such fundamental knowledge.

